Introduction
Atherosclerotic cardiovascular disease (ASCVD) is one of the most important global causes of morbid-ity and mortality. Within the last decade, many guidelines have been produced that emphasize the role of statin treatment in high-risk individuals to reduce cardiovascular risks by decreasing the low-density lipoprotein cholesterol (LDL-C) concentrations. In 2001, the National Cholesterol Education Program Expert Panel for the Detection, Evaluation and Treatment of High Blood Cholesterol in Adults released their third report (NCEP-ATP III) 1) and within three years, these guidelines were updated 2) . The Screening for Heart Attack Prevention and Education (SHAPE) task force were collected after an overnight fast. The measurement techniques included an enzymatic colorimetric assay for the serum total cholesterol (TC) and triglyceride (TG) levels and direct measurement using a homogenous enzymatic colorimetric assay for the LDL-C and high-density lipoprotein cholesterol (HDL-C) levels, which were analyzed using Roche Diagnostics reagent kits on an automated chemistry analyzer (Modular DPP; Roche Diagnostics, Tokyo, Japan). The high-sensitivity C-reactive protein (hs-CRP) level was analyzed according to particleenhanced immunonephelometry with the BNII System (Dade Behring, Marburg, Germany) using a lower limit of detection of 0.175 mg/L.
Questionnaires were used to ascertain information regarding alcohol consumption (glass/day), smoking (never, ex, current) and the frequency of moderate activity per week. Moderate activity was defined as more than 30 minutes of activity per day that induced slight breathlessness.
CT scanning was performed with a 64-slice MDCT scanner (Lightspeed VCT XTe-64 slice; GE Healthcare, Milwaukee, WI) using the following standard scanning protocol: 32 0.625-mm section collimation, 400-msec rotation time, 120-kV tube voltage and a tube current of 31 mAS (310 mA 0.1 sec) under electrocardiographic-gated dose modulation. Quantitative CAC scores were calculated according to the method described by Agatston et al. 5) . Abdominal ultrasonography (Logic Q700 MR; GE, Milwaukee, WI, USA) using a 3.5-MHz probe was performed in all subjects by experienced clinical radiologists, and fatty liver was diagnosed based on standard criteria, including hepatorenal echo contrast, liver brightness and vascular blurring. Mild fatty infiltration was classified as a minimal increase in the echogenicity of the liver compared with that of the renal cortex, in which the diaphragm and intrahepatic vessels appeared normal. Moderate to severe fatty infiltration was classified based on a moderate increase in echogenicity of the liver and slightly impaired appearance of the diaphragm and intrahepatic vessels or a marked increase in liver echogenicity with poor penetration of the deep parenchyma and impaired visualization of the intrahepatic vessels and diaphragm 6) . The KNHANES is a cross-sectional, nationwide, population-based survey that has been conducted periodically since 1998 to assess the health and nutritional status of the South Korean population. KNHANES V data (available at https://knhanes.cdc.go.kr) were collected between 2008 and 2010. We analyzed the findings for 16,892 subjects over 20 years of age with available 10-hour fasting data. There were 7,060 men report was published in 2006 3) , and further guidelines followed in November 2013, with the ACC/AHA guidelines for the treatment of blood cholesterol to reduce ASCVD 4) . This new set of guidelines identifies four major groups in whom ASCVD risk reduction with statin treatment may produce benefits: 1) subjects with clinical evidence of ASCVD, including coronary heart disease, stroke and peripheral arterial disease, 2) subjects with primary causes of an LDL-C level of 190 mg/dL, 3) subjects with diabetes, an age of 40 to 75 years and an LDL-C concentration of 70 to 189 mg/dL but without evidence of ASCVD and 4) subjects with no clinical evidence of ASCVD or diabetes who exhibit an LDL-C level of 70 to 189 mg/dL and an estimated 10-year ASCVD risk of ≥ 7.5% 4) . The advice for people in the first three groups is similar to that published previously; however, advocating treatment for the fourth group is new and potentially very controversial, with major implications for public health. Furthermore, the development of these new guidelines was based predominantly on randomized placebo controlled trials in Western populations 4) , and the applicability of the trial data to Asian populations remains unclear. Since there are considerable public health implications for widespread statin use in the fourth group, which includes individuals without evidence of disease, we evaluated the proportion of people who would qualify for statin treatment according to these guidelines in a population-based cohort of Korean subjects.
Methods
The study population consisted of individuals who underwent comprehensive health examinations in 2010 at Kangbuk Samsung Hospital, College of Medicine, Sungkyunkwan University in South Korea. The population included 8,742 participants 40~75 years of age who received a coronary artery calcium (CAC) score following coronary CT scanning. The study protocol was approved by the institutional review board at Kangbuk Samsung Hospital. Informed consent requirement was waived because personal identifying information was not accessed. Our study population is not a fully representative randomized sample of the Korean population. Therefore, in order to evaluate whether the results of our study are representative of the results for a randomized sample of the Korean population, we compared our findings with the data obtained from the Korea National Health and Nutrition Examination Survey (KNHANES).
BMI was calculated as weight in kilograms divided by height in meters squared. Blood samples 1). Among the subjects with an ASCVD 10-year risk of ≥ 7.5%, men had lower HDL-C levels, higher TC levels, systolic blood pressure (SBP) values and frequency of DM and a significantly higher rate of smoking than women (Supplementary Table 2) . Table 2 presents the proportion of subjects with an ASCVD 10-year risk equal to or above 7.5% and an LDL-C level equal to or above 70 mg/dL according to age group in the 2008-2010 KNHANES data. These results were very similar to our findings. For example, the proportion of subjects with an ASCVD 10-year risk of ≥ 7.5% significantly increased in association with age in both men and women (p 0.001 in both sexes). Moreover, the proportion of subjects with both an ASCVD 10-year risk of ≥ 7.5% and LDL-C level of ≥ 70 mg/dL (who would therefore qualify for statin treatment according to the new guidelines) increased with age in both men and women (p 0.001 for both sexes). These results also showed that over 85.0% of men ≥ 60 years of age and over 95.0% of women ≥ 70 years of age had an ASCVD 10-year risk of ≥ 7.5% and LDL-C level of ≥ 70 mg/dL ( Table 2) . Table 3 presents the characteristics of the subjects according to the ASCVD risk quartiles for men and women. The individuals in the highest ASCVD risk quartile were older and smoked more frequently. Furthermore, these subjects had higher BMI, waist circumference and SBP and diastolic blood pressure (DBP) values and more unfavorable cardiometabolic and lipid profiles. Metabolic syndrome, hypertension and diabetes were also more prevalent among the subjects in the highest ASCVD risk quartile for both men and women ( Table 3) .
The prevalence of fatty liver also increased with an increasing ASCVD 10-year risk quartile, with an increasing linear trend in both men and women (p value for the trend 0.001 in men; and p value for the trend 0.001 in women) (Fig. 1) . In addition, the proportion of subjects with a 10-year Framingham risk score of ≥ 10% increased in association with the ASCVD 10-year risk quartile in both men and women ( Fig. 1) , and the number of subjects with an increased coronary artery calcium score of 20 and 100 increased with an increasing ASCVD 10-year risk quartile in both sexes (p-values for men and women all 0.001) (Fig. 1) .
Finally, age was found to be significantly correlated with the ASCVD 10-year risk in both men and women (r 0.579, p 0.001 in men without DM, r 0.764, p 0.001 in women without DM) (Fig. 2) . and 9,832 women (58.2% of the total subjects), including 5,377 subjects over 60 years of age (31.8% of the total subjects).
Statistical Analysis
The statistical analysis of the data was performed using the SPSS version 15.0 software program (SPSS, Point Richmond, CA, USA). Continuous variables are expressed as the mean SD for normally distributed variables and the median (interquartile range) for other variables. The ASCVD risk was stratified into quartiles. Categorical variables are expressed as percentages and were compared between groups using the 2 test. The association between age and the 10-year ASCVD risk was evaluated according to a Pearson's correlation analysis.
Results
Among the 8,742 individuals (7,197 men), 81.4%, 16.0%, 2.1% and 0.4% were in the 40-49 years, 50-59 years, 60-69 years and 70-75 years age groups, respectively. For men, 82.1%, 15.9%, 1.7% and 0.3% were in the 40-49 years, 50-59 years, 60-69 years age and 70-75 years age groups, respectively. Table 1 presents the proportion of subjects with an ASCVD 10-year risk of ≥ 7.5% and/or LDL-C level of ≥ 70 mg/dL stratified by age group and sex. The proportion of subjects with an ASCVD 10-year risk of ≥ 7.5% significantly increased with age in both men and women (p 0.001 in both sexes), irrespective of diabetes mellitus (DM). In addition, the proportion of subjects with an LDL-C level of ≥ 70 mg/dL was associated with age in women (p 0.017 in total subjects, p 0.024 in subjects without DM), with a non-significant trend in men (p 0.092 in total subjects, p 0.250 in subjects without DM). Furthermore, the proportion of subjects with both an ASCVD 10-year risk of ≥ 7.5% and LDL-C level of ≥ 70 mg/dL (who would therefore qualify for statin treatment according to the new guidelines) increased in association with age for both men and women (p 0.001 for both sexes), irrespective of DM. Approximately 90% of men ≥ 60 years of age and women ≥ 70 years of age had an estimated ASCVD 10-year risk of ≥ 7.5% and an LDL-C level of ≥ 70 mg/dL ( Table 1 ).
An estimated Framingham 10-year risk of cardiovascular disease (CVD) of ≥10% was significantly associated with an ASCVD 10-year risk of ≥ 7.5% among both men and women (p 0.001 in both sexes). A total of 89.6% of men and 18.8% of women with an ASCVD 10-year risk of ≥ 7.5% had a Framingham 10-year CVD risk of ≥ 10.0% (Supplementary Table quartiles in both men and women (all p-values 0.001).
ASCVD is one of the most important global causes of morbidity and mortality, and the most significant treatable risk factor is LDL-C. Until recently, many Western guidelines have focused on LDL-C reduction and the use of statins for the treatment and prevention of CVD [1] [2] [3] . Although there is new concern that statins increase the risk of incident diabetes 8) , it is widely accepted that in high-risk patients, the benefits clearly outweigh the risks 9, 10) . The new guidelines rec-
Discussion
Our data showed that approximately 90% of Korean men and women ( ≥ 60 and ≥ 70 years of age, respectively) without ASCVD would require take statin treatment according to the new ASCVD guidelines. Interestingly, NAFLD is now accepted to be an independent cardiovascular risk factor 7) , and our results clearly showed that the proportion of subjects with fatty liver increased across the ASCVD 10-year risk . There may be a case for the high frequency of use of statin treatment in these groups. ASCVD events occur after age 70, resulting in the greatest potential for highest absolute risk reduction in this age group 4) and CVD is usually more hazardous in older patients 12) . However, that said, the willingness to take statin medications is highly sensitive to the occurrence of statin-associated side effects, such as mild fatigue, muscle aches and pain or fuzzy thinking in older persons 13) . To date, there are few data from communitybased studies showing the effects of statin treatment in older subjects without CVD 14) . One study of 25,378 older women suggested that the duration and potency of statin therapy are not associated with the onset of frailty 15) . Furthermore, another cohort study of subjects 65 years of age or older reported that the incidence of colorectal, lung and breast cancer in people treated with statins (n 24,439) is very similar to the rates for these diseases observed in the general population 16) . Statin treatment causes several adverse side effects, including myalgia, creatinine kinase elevation, transaminase elevation and, very rarely, rhabdomyolysis. A meta-analysis of 35 trials involving 74,102 subjects concluded that statin therapy is associated with only a small excess risk of transaminase elevation and not an increased risk of myalgia, creatine kinase elevation, rhabdomyolysis or withdrawal of therapy compared with a placebo 17) . Furthermore, several studies have recommended strategies to enhance the safety of statins in elderly patients 14, 18, 19) . Generally, women show later onset and a lower ommend statin treatment for individuals without evidence of clinical ASCVD or diabetes who exhibit an LDL-C level of 70-189 mg/dL and an estimated 10-year ASCVD risk of 7.5% 4) . The new guidelines recommend the use of the 10-year ASCVD risk threshold in both white and black men and women, and it is uncertain whether such a threshold should be applied to Asian populations 4) . In the current study, an ASCVD 10-year risk of ≥ 7.5% was found to be significantly correlated with a Framingham 10-year risk score of ≥ 10%, and this relationship was more pronounced in men than women. This sex difference is due to the poorer cardiometabolic status of men compared to women. The new ASCVD risk calculator uses several risk factors, including sex, age, race, smoking status, TC, HDL-C, SBP and treatment for high blood pressure or diabetes 4) . The Framingham 10-year risk score, applied in the NCEP-ATP III study, uses similar risk factors (age, sex, TC and HDL-C concentrations, smoking status, SBP, history of diabetes and use of antihypertensive medications) 1, 11) . These risk factors are widely accepted to be the major risk factors for CVD. However, the Framingham risk score is also intended to be used to predict death due to myocardial infarction and coronary heart disease, whereas ASCVD risk prediction incorporates the risk of coronary heart disease, stroke and peripheral artery disease 1, 3) . The present study showed that approximately 90% of men ≥ 60 years of age and women ≥ 70 years of age in our study population and approximately 85% of men ≥ 60 years of age and 95% of women ≥ 70 years of age in the KNHANES population would A B uated few women 14, 22) . Therefore, we also assessed the 2008-2010 KNHANES data. In this registry, we analyzed data for 16,892 subjects, including 9,832 women (58.2% of the total subjects) and 5,377 subjects over 60 years of age (31.8% of the total subjects). Comparing our study findings to that obtained for the KNHANES population, the results for the two populations were found to be very similar. Taking into account the fact that the KNHANES population constitutes a representative randomized sample of the Korean population, we believe that the results of our study are meaningful. Second, our study population included only Koreans. Several studies have revealed ethnic differences within Asian populations in terms of cardiovascular mortality, with Chinese subjects having the lowest prevalence of coronary heart disease and rate of mortality from ischemic heart disease 29, 30) . Therefore, more studies regarding ethic differences in the prevalence, mortality and prevention of ASCVD in Asian populations are needed.
Conclusions
Given the costs, known side effects and public health implications of statin treatment, we conclude that Asian-specific guidelines are needed to avoid unnecessary over treatment in a large number of peoprevalence of cardiovascular disease than men 20) . Most previous statin trials have included few women ( 25%) and either did not report sex-specific results or reported aggregate events (e.g., major coronary events) and not individual outcomes 21) . However, one review commented that statin therapy, in addition to diet and exercise, in 'moderately hyperlipidemic women' without a previous history of cardiovascular disease provides a significant benefit in preventing coronary heart disease events 21) . Moreover, another Asian study concluded that treatment with a statin (pravastatin) in women with increased cholesterol levels but no history of cardiovascular disease provides a benefit similar to that seen in men, with the benefit being more marked in older women 22) . Finally, in our study, women 70 years of age had a significantly higher estimated absolute ASCVD risk than the women 60-70 years of age. As the absolute risk of CVD is higher in older age groups, these findings support the use of treatment with statins in this age group.
In 2009 and 2012, two Korean studies revealed that the NECP-ATP III guidelines (the most popular Western guidelines for the primary and secondary prevention of cardiovascular disease) were not completely suitable for the Korean population 23, 24) . Additionally, several Japanese studies have reported the clinical significance of statin therapy for the primary and secondary prevention of cardiovascular disease. However, controversial results were obtained with respect to a lower LDL-C level as a better factor in the Japanese population according to Western guidelines 25, 26) . The Japanese guidelines for the diagnosis and prevention of ASCVD were published in 2012 27) . The incidence of coronary artery disease is lower in Japanese individuals than Westerners. Therefore, the Japanese guidelines used different risk calculation methods and include different treatment indications than those applied in Western guidelines. Furthermore, the treatment goals for LDL-C are more generous than previous Western guidelines 27) , and current Japanese guidelines comprise more distinct features (presence of numerical goals for lipid control, the use of non-statin drugs and the application of a risk chart based on the NIPPON DATA80) compared to the 2013 ACC/AHA guidelines. Furthermore, the Japanese guidelines are known to be more useful in the Japanese population than the 2013 ACC/AHA guidelines 28) . Therefore, Asian-specific guidelines are needed for Asian populations.
Our study is associated with several limitations. First, our study population included few subjects over 70 years of age (0.4%) and few women (17.7%). However, there are few data for older populations without cardiovascular disease, and most statin trials have eval- 
